ESPL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Analogous observations have been reported for chronic myeloid leukemia (CML) where clonal evolution and progression time from chronic phase to blast crisis correlated with enhanced proteolytic activity of separase in patients with BCR-ABL e14a2 fusion type CML under treatment with the tyrosine kinase inhibitor imatinib [30].